Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for neuroimmune and inflammatory indications with high unmet medical need. The company concentrates on modulating biological pathways such as the lysophosphatidic acid 1 receptor and the muscarinic type 1 receptor to treat diseases including idiopathic pulmonary fibrosis chronic pain major depressive disorder and relapsing remitting…
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for neuroimmune and inflammatory indications with high unmet medical need. The company concentrates on modulating biological pathways such as the lysophosphatidic acid 1 receptor and the muscarinic type 1 receptor to treat diseases including idiopathic pulmonary fibrosis chronic pain major depressive disorder and relapsing remitting multiple sclerosis. Its pipeline consists of internally discovered drug candidates PIPE-791 and PIPE-307 as well as earlier stage programs such as CTX-343.
Contineum Therapeutics generates revenue primarily through collaboration agreements licensing deals and related financial incentives. The company has entered into an exclusive worldwide license agreement with Johnson & Johnson for its PIPE-307 asset under which it received an upfront cash payment of $50 million and a $25 million equity investment and is eligible to receive milestone payments that could total up to $1 billion plus tiered royalties on future net sales. No product sales have been recorded to date as all drug candidates remain in clinical or pre clinical development.
Contineum Therapeutics positions itself as an innovative player in the small molecule biotechnology space competing against larger pharmaceutical firms and other biotech companies developing therapies for similar indications. In idiopathic pulmonary fibrosis the company faces competition from approved agents such as pirfenidone nintedanib and nerandomilast as well as from other LPA1R antagonists in clinical development including molecules from Bristol Myers Squibb AbbVie and Structure Therapeutics. For depression and relapsing remitting multiple sclerosis the company competes with established antidepressants and disease modifying therapies offered by companies such as Eli Lilly GlaxoSmithKline Novartis and Roche. Contineum believes its competitive advantages stem from its proprietary chemistry platform the brain penetrant profile of PIPE-791 the selective nature of PIPE-307 and its strategic partnership with Johnson & Johnson which provides access to extensive resources and commercialization expertise.
Contineum Therapeutics serves patients suffering from idiopathic pulmonary fibrosis chronic pain major depressive disorder and relapsing remitting multiple sclerosis. The company also works with collaborative partners such as Johnson & Johnson to advance its clinical programs. Specific individual customer names are not disclosed in the filing.